



Partner

Boston | One International Place, 40th Floor, 100 Oliver Street, Boston, MA, United States of America 02110-2605

T +1 617 728 7100 | F +1 617 426 6567

chad.davis@dechert.com

Services

Intellectual Property > Patent Counseling and Prosecution >
IP and Technology Licensing and Transactions > Life Sciences > Chemical >
Health Care > IP Due Diligence >

Dr. Chad E. Davis counsels companies, investors, and entrepreneurs on intellectual property matters, especially patent matters. Dr. Davis has extensive experience in prosecution and strategic development of worldwide patent portfolios, intellectual property due diligence, risk assessment through, for example, validity and infringement analyses, post-grant patent proceedings, and intellectual property contracts.

Dr. Davis represents clients in a diverse range of technologies, including pharmaceuticals, drug delivery technologies, crystal forms, organic dyes, chemical processes, polymers, proteins, antibodies, stem cell technology, medical diagnostics, medical imaging, microfluidic devices, adhesives, analytical chemistry, foams, cosmetics, and optical technologies. For companies developing pharmaceuticals, Dr. Davis provides counsel through all aspects of the business cycle with particular acumen for developing and implementing strategies to maximize worldwide patent and regulatory exclusivities for the pharmaceutical product.

In 2019, Dr. Davis was recognized by *The Legal 500* US for Industry focus: Healthcare: Life Sciences. Dr. Davis was also recognized by the *National Law Journal* as a “Rising Star” in the Boston area. Prior to joining Dechert, Dr. Davis was a partner at another law firm.

EXPERIENCE

- **Centrexion Therapeutics Corporation**, a pharmaceutical company developing medicines to treat pain, to manage intellectual property matters including development and implementation of strategies to procure patent protection for multiple small molecule therapeutic agents in human clinical trials
- **Lycera Corporation**, a pharmaceutical company developing medicines to treat autoimmune disease and cancer, to manage intellectual property matters including development and implementation of strategies to procure patent protection for multiple small molecule therapeutic agents in human clinical trials
- **Rafael Pharmaceuticals, Inc.**, a pharmaceutical company developing medicines to treat cancer, to manage intellectual property matters including development and implementation of strategies to procure patent protection for small molecule therapeutic agents being developed for treatment of cancer
- Implements patent portfolio strategies to establish domestic and international patent protection and performs intellectual property due diligence investigations on behalf of investors, financial institutions, and companies in advance of investments in privately held companies and public offerings of securities for public companies
- Counsels clients on intellectual property risk assessment, post-grant patent proceedings and disputes concerning ownership, inventorship, validity and infringement of intellectual property rights
- Develops strategies for maximizing worldwide patent and regulatory exclusivities for companies developing pharmaceuticals
- Counsels clients on intellectual property contract matters

Includes matters handled at Dechert or prior to joining the firm.

EDUCATION

- Ball State University, B.S., 1998, *summa cum laude*
- University of Illinois at Urbana-Champaign, Ph.D., Chemistry, 2003
- Boston College Law School, J.D., 2007

ADMISSIONS

- Massachusetts
- United States Patent and Trademark Office

MEMBERSHIPS

- American Chemical Society
- American Intellectual Property Law Association
- Intellectual Property Owners Association

SPEAKING ENGAGEMENTS

- **3rd Annual Life-Sciences Patent Network Spring Conference** — Boston, MA (April 25, 2019)

Moderator, "IP Portfolio Management: In-house Counsel Day-to-Day Challenges in Prosecuting and Enforcing Patents."
- **US Life Sciences Industry in the 2018 Landscape: Significant Trends and Developments Explored Webcast** — The Knowledge Group (September 5, 2018)